187 related articles for article (PubMed ID: 9393874)
1. Choline kinase inhibitors as a novel approach for antiproliferative drug design.
Hernández-Alcoceba R; Saniger L; Campos J; Núñez MC; Khaless F; Gallo MA; Espinosa A; Lacal JC
Oncogene; 1997 Nov; 15(19):2289-301. PubMed ID: 9393874
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells.
Ramírez de Molina A; Rodríguez-González A; Penalva V; Lucas L; Lacal JC
Biochem Biophys Res Commun; 2001 Jul; 285(4):873-9. PubMed ID: 11467831
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells.
Rodríguez-González A; Ramírez de Molina A; Fernández F; Ramos MA; del Carmen Núñez M; Campos J; Lacal JC
Oncogene; 2003 Dec; 22(55):8803-12. PubMed ID: 14654777
[TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery.
Hernández-Alcoceba R; Fernández F; Lacal JC
Cancer Res; 1999 Jul; 59(13):3112-8. PubMed ID: 10397253
[TBL] [Abstract][Full Text] [Related]
5. The choline kinase inhibitor hemicholinium-3 can inhibit mitogen-induced DNA synthesis independent of its effect on phosphocholine formation.
Crilly KS; Tomono M; Kiss Z
Arch Biochem Biophys; 1998 Apr; 352(1):137-43. PubMed ID: 9521826
[TBL] [Abstract][Full Text] [Related]
6. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action.
Rodríguez-González A; Ramirez de Molina A; Fernández F; Lacal JC
Oncogene; 2004 Oct; 23(50):8247-59. PubMed ID: 15378008
[TBL] [Abstract][Full Text] [Related]
7. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression.
Ramírez de Molina A; Báñez-Coronel M; Gutiérrez R; Rodríguez-González A; Olmeda D; Megías D; Lacal JC
Cancer Res; 2004 Sep; 64(18):6732-9. PubMed ID: 15374991
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors.
Cuadrado A; Carnero A; Dolfi F; Jiménez B; Lacal JC
Oncogene; 1993 Nov; 8(11):2959-68. PubMed ID: 8414498
[TBL] [Abstract][Full Text] [Related]
9. Increased synthesis of phosphocholine is required for UV-induced AP-1 activation.
Dong Z; Huang C; Ma WY; Malewicz B; Baumann WJ; Kiss Z
Oncogene; 1998 Oct; 17(14):1845-53. PubMed ID: 9778051
[TBL] [Abstract][Full Text] [Related]
10. Activation of type D phospholipase by serum stimulation and ras-induced transformation in NIH3T3 cells.
Carnero A; Cuadrado A; del Peso L; Lacal JC
Oncogene; 1994 May; 9(5):1387-95. PubMed ID: 8152799
[TBL] [Abstract][Full Text] [Related]
11. From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design.
Ramírez de Molina A; Rodríguez-González A; Lacal JC
Cancer Lett; 2004 Apr; 206(2):137-48. PubMed ID: 15013519
[TBL] [Abstract][Full Text] [Related]
12. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity.
Lucas L; Hernández-Alcoceba R; Penalva V; Lacal JC
Oncogene; 2001 Mar; 20(9):1110-7. PubMed ID: 11314048
[TBL] [Abstract][Full Text] [Related]
13. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
He H; Hirokawa Y; Levitzki A; Maruta H
Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
[TBL] [Abstract][Full Text] [Related]
14. QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be?
Campos J; Núñez MC; Conejo-García A; Sánchez-Martín RM; Hernández-Alcoceba R; Rodríguez-González A; Lacal JC; Gallo MA; Espinosa A
Curr Med Chem; 2003 Jul; 10(13):1095-112. PubMed ID: 12678804
[TBL] [Abstract][Full Text] [Related]
15. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy.
Ramírez de Molina A; Gutiérrez R; Ramos MA; Silva JM; Silva J; Bonilla F; Sánchez JJ; Lacal JC
Oncogene; 2002 Jun; 21(27):4317-22. PubMed ID: 12082619
[TBL] [Abstract][Full Text] [Related]
16. New non-symmetrical choline kinase inhibitors.
Schiaffino-Ortega S; López-Cara LC; Ríos-Marco P; Carrasco-Jimenez MP; Gallo MA; Espinosa A; Marco C; Entrena A
Bioorg Med Chem; 2013 Nov; 21(22):7146-54. PubMed ID: 24080101
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism.
Rodríguez-González A; Ramírez de Molina A; Bañez-Coronel M; Megias D; Lacal JC
Int J Oncol; 2005 Apr; 26(4):999-1008. PubMed ID: 15753995
[TBL] [Abstract][Full Text] [Related]
18. Method of identifying inhibitors of oncogenic transformation: selective inhibition of cell growth in serum-free medium.
Li PM; Fukazawa H; Yamamoto C; Mizuno S; Tanaka K; Hori M; Yaginuma S; Saito T; Uehara Y
Oncogene; 1993 Jul; 8(7):1731-5. PubMed ID: 8510919
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
[TBL] [Abstract][Full Text] [Related]
20. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
